Flecainide
Treatment for Atrial Fibrillation
Typical Dosage: 50-150 mg twice daily
Effectiveness
65%
Safety Score
55%
Clinical Trials
48
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
50-150 mg twice daily
Time to Effect
1-2 days
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$750
Side Effect Mgmt:$500
Total Annual:$1,450
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$40,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$2,636
Cost per Remission
$3,222
Comparison vs Metoprolol
Cost Difference
+$300/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Flecainide Outcomes
for Atrial Fibrillation
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+55%
Remission Rate
+45%
Common Side Effects
Dizziness
+15%
Visual disturbances
+10%
Proarrhythmia (ventricular tachycardia/fibrillation)
+3%
Nausea
+7%
Sources:
Active Clinical Trials
3 active trials recruiting for Flecainide in Atrial Fibrillation
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
NCT02347111RECRUITINGPHASE4
162 participants
INTERVENTIONAL
Chicago, United States +3 more
Started: Dec 31, 2020
Dronedarone Rhythm Intervention for Early Atrial Fibrillation
NCT07270848NOT YET RECRUITINGPHASE4
1.9K participants
INTERVENTIONAL
Incheon, South Korea +15 more
Started: Jan 1, 2026
Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia
NCT05213104ACTIVE NOT RECRUITINGPHASE3
186 participants
INTERVENTIONAL
Paris, France
Started: Mar 23, 2022
Completed Clinical Trials
9 completed trials for Flecainide in Atrial Fibrillation
Flecainide-Short Long Study (Flec-SL)
NCT00215774COMPLETEDNA
760 participants
INTERVENTIONAL
Started: Mar 1, 2005
INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)
NCT03539302COMPLETEDPHASE2
176 participants
INTERVENTIONAL
Bonheiden, Belgium +8 more
Started: May 29, 2018
Predictive Factors to Effectively Terminate Paroxysmal Atrial Fibrillation by Blocking Atrial Selective Ionic Currents
NCT03005366COMPLETEDPHASE4
50 participants
INTERVENTIONAL
Madrid, Spain
Started: Jan 1, 2017
To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation
NCT00189319COMPLETEDPHASE4
200 participants
INTERVENTIONAL
Lille, France
Started: Sep 1, 2003
Beta Blockers Plus Intravenous Flecainide for Paroxysmal Atrial Fibrillation: a Real-world Chios Registry (BETAFLEC-CHIOS)
NCT04991896COMPLETED
81 participants
OBSERVATIONAL
Chios, Greece
Started: Jan 1, 2020
Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency Department
NCT02248753COMPLETEDNA
437 participants
INTERVENTIONAL
Amsterdam, Netherlands +14 more
Started: Oct 1, 2014
A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation
NCT00408200COMPLETEDNA
110 participants
INTERVENTIONAL
Philadelphia, United States +1 more
Started: Nov 1, 2006
The Use of Flecainide for Treatment of Atrial Fibrillation
NCT05084495COMPLETED
50 participants
OBSERVATIONAL
Helsingborg, Sweden
Started: Feb 1, 2022
Management of Atrial Fibrillation With Flecainide : the AFFLEC Study
NCT02190175COMPLETED
100 participants
OBSERVATIONAL
Athens, Greece +2 more
Started: Jun 1, 2014
Showing 20 of 49 total trials